HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight Has Growth Hero In Hero Acne Products, Optimism For Broader Sales Stabilization

Executive Summary

Reported revenues for January-March up 10.2% to $1.43bn, with around half the growth coming on sales of Hero Mighty Patch acne treatments. Price increases drove Q1 revenue growth across other categories with volume largely flat.

You may also be interested in...



Church & Dwight Cuts ‘Power’ Brands To Seven While Reporting, Forecasting Bigger Results

Health, personal and household care product marketer says raising its annual guidance model from 3% organic growth to 4% driven by expectations for international sales growth, a return to volume-driven sales growth and outlook for Hero and TheraBreath brands.

Whether Higher Sales Or Lower Volumes, Price Increases Make Presence Known For P&G And C&D

Both health, wellness and beauty product marketers on report increased prices helped drive revenue growth during April-June period while also factoring in lower sales volumes.

US Q2 Consumer Health Earnings Preview: Two Firsts On Table For Perrigo, One For Kenvue

Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel